Truist analyst Danielle Brill raised the firm’s price target on Palvella Therapeutics (PVLA) to $80 from $56 and keeps a Buy rating on the shares. The firm is updating its model following its meetings with the company management as conversations focused on the conviction in MLM – microcystic lymphatic malformations – Phase 3 trial success/ rationale for trial design, confidence in the MLM commercial opportunity, and expectations for upcoming Phase 2 proof of concept data in CVM, cutaneous venous malformations, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics price target raised to $95 from $75 at H.C. Wainwright
- Palvella Expands QTORIN Gel Program for Rare Disease
- Buy Rating for Palvella Therapeutics Driven by Strategic Expansion of QTORIN Rapamycin for Unmet CSA Treatment
- Palvella Therapeutics: Expanding Market Potential with QTORIN 3.9% Rapamycin for Angiokeratomas
- Palvella Therapeutics price target raised to $80 from $60 at Stifel